Seeking Alpha

CombiMatrix's (CBMX) decision to shift its focus to prenatal testing and away from oncology...

CombiMatrix's (CBMX) decision to shift its focus to prenatal testing and away from oncology looks to be bearing fruit, with the company saying that it achieved preliminary annual growth rates of 172% in Q4 and 171% in the full year for prenatal diagnoses. Overall testing grew 21% and 25% respectively. Shares sky 21%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|